Substance / Medication

Mosunetuzumab

Overview

Active Ingredient
mosunetuzumab
RxNorm CUI
2625122
Labeler: Genentech, Inc.Updated: 2025-12-19T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Dosage and Administration (2.1 2.4) Warnings and Precautions (5.1) [seeandand] Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO VELO. Initiate treatment with the LUNSUMIO VELO step-up dosing schedule to reduce the risk of CRS.

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch Francesc, Kuruvilla John, Vassilakopoulos Theodoros P et al. · Clin Lymphoma Myeloma Leuk · 2024
PMID: 37981564Meta-Analysis
Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma.
Ray Markqayne D, Kanters Steve, Beygi Sara et al. · Transplant Cell Ther · 2024
PMID: 38901633Observational
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States.
Oluwole Olalekan O, Ray Markqayne D, Zur Richard M et al. · Front Immunol · 2024
PMID: 38855109ObservationalFull text (PMC)
Mosunetuzumab-associated fatal HHV-6 encephalitis in a patient with follicular lymphoma.
Samperio Victor M, Hamoud Moza, Dasanu Constantin A · J Oncol Pharm Pract · 2025
PMID: 40625203Case Report
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
Tadmor Tamar, Levy Yurkovski Ilana · Leuk Lymphoma · 2024
PMID: 38247446Case Report
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.
Thiruvengadam Swetha Kambhampati, Popplewell Leslie L, Herrera Alex F et al. · Br J Haematol · 2026
PMID: 41254806TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mosunetuzumab (substance)
SNOMED CT
278181000202107
UMLS CUI
C4763385
RxNorm CUI
2625122
Labeler
Genentech, Inc.

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.